BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 11074613)

  • 1. Blood and serum substances for markers of prostate cancer.
    Bangma CH; Verhagen PC
    Microsc Res Tech; 2000 Dec; 51(5):430-5. PubMed ID: 11074613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer.
    Hara N; Kasahara T; Kawasaki T; Bilim V; Obara K; Takahashi K; Tomita Y
    Clin Cancer Res; 2002 Jun; 8(6):1794-9. PubMed ID: 12060619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR.
    Fuessel S; Sickert D; Meye A; Klenk U; Schmidt U; Schmitz M; Rost AK; Weigle B; Kiessling A; Wirth MP
    Int J Oncol; 2003 Jul; 23(1):221-8. PubMed ID: 12792797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
    Mikolajczyk SD; Rittenhouse HG
    Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum markers for prostate cancer: a rational approach to the literature.
    Steuber T; O'Brien MF; Lilja H
    Eur Urol; 2008 Jul; 54(1):31-40. PubMed ID: 18243505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Detection of PSA mRNA in prostate cancer patients' blood].
    Ito T; Okubo Y; Tachibana M
    Rinsho Byori; 2001 Oct; 49(10):974-7. PubMed ID: 11769474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
    Tsuchiya N; Ohyama C; Habuchi T
    Gan To Kagaku Ryoho; 2005 Feb; 32(2):275-80. PubMed ID: 15751649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biomarkers for prostate cancer in predicting diagnosis, staging and prognosis].
    Ohori M
    Gan To Kagaku Ryoho; 2009 Jan; 36(1):6-10. PubMed ID: 19151558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
    Antunes AA; Leite KR; Sousa-Canavez JM; Camara-Lopes LH; Srougi M
    J Urol; 2009 Feb; 181(2):594-600. PubMed ID: 19084862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Early detection of prostatic cancer].
    Weissbach L
    Urologe A; 1992 Jul; 31(4):193-4. PubMed ID: 1381124
    [No Abstract]   [Full Text] [Related]  

  • 12. The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer.
    Mearini E; Antognelli C; Del Buono C; Cochetti G; Giannantoni A; Nardelli E; Talesa VN
    Biomarkers; 2009 Jun; 14(4):235-43. PubMed ID: 19489685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
    Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
    J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reverse transcriptase-polymerase chain reaction and immunohistochemical studies for detection of prostate stem cell antigen expression in prostate cancer: potential value in molecular staging of prostate cancer.
    Joung JY; Yang SO; Jeong IG; Han KS; Seo HK; Chung J; Park WS; Lee KH
    Int J Urol; 2007 Jul; 14(7):635-43. PubMed ID: 17645609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Quantitative detection of differential display code 3 mRNA in peripheral blood of patients with prostate cancer].
    Weng ZL; Yu KY; Mao XL; Tao ZH; Chen XD; Wu XL; Hu YP; Wang SQ; Li CD; Chen ZG
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(41):2911-5. PubMed ID: 17288789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
    Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
    Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA
    Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New test detects early prostate cancer.
    Health News; 2005 Sep; 11(9):9. PubMed ID: 16208809
    [No Abstract]   [Full Text] [Related]  

  • 19. Serum soluble Fas level for detection and staging of prostate cancer.
    Furuya Y; Fuse H; Masai M
    Anticancer Res; 2001; 21(5):3595-8. PubMed ID: 11848529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue.
    Lintula S; Stenman J; Bjartell A; Nordling S; Stenman UH
    Prostate; 2005 Jun; 63(4):324-9. PubMed ID: 15599939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.